Summary
- Today, we put developmental concern Altimmune back in the spotlight for the first time in 18 months.
- The company is targeting some very large markets with candidates in its pipeline and has some near-term potential catalysts on the horizon.
- An investment analysis follows in the paragraphs below.
- Looking for a portfolio of ideas like this one? Members of The Biotech Forum get exclusive access to our model portfolio. Learn More »
Today, we revisit Altimmune (NASDAQ:ALT) for the first time in a year and a half. We concluded that article noting the shares seemed worthy of a small ‘watch item‘ position pending further developments. The stock has been on a big tear recently, rising up to 52-week highs. Therefore, it seems a good time to circle back on this small biotech name. An analysis follows below.
Company Overview:
Altimmune is a clinical stage developmental concern based out of Maryland. In our last article, we spent some time discussing the company’s Covid development efforts, which are no longer being prioritized. In fact, they have discontinued all activities around their T-Covid program.
May Company Presentation
The company’s lead product candidate is called pemvidutide. This is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. In January of this year, the FDA approved the company’s Investigational New Drug or IND application for its Phase 2 clinical trial of pemvidutide for obesity.
